Trials / No Longer Available
No Longer AvailableNCT01776996
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Continued Access Arm | All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day. |
Timeline
- First posted
- 2013-01-28
- Last updated
- 2017-04-06
Locations
28 sites across 7 countries: Argentina, Belgium, Italy, Poland, Russia, South Africa, Switzerland
Source: ClinicalTrials.gov record NCT01776996. Inclusion in this directory is not an endorsement.